Moleculin Biotech (MBRX)

• Market cap: $10.2M
• 1 day: 0%
• 5 days: 1.48%
• 1 month: -16.26%
• 3 months: -48.63%
• 6 months: -79.82%
• Year to date: -43.09%
• 1 year: -92.44%
• 5 years: -99.87%
• 10 years: -99.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Employees: 17